These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 14688524)

  • 21. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis.
    Zucker MJ; Baran DA; Arroyo LH; Goldstein DJ; Neacy C; Mele L; Weinberg AD; Prendergast TW; Ribner HS
    Transplant Proc; 2005 Jun; 37(5):2231-9. PubMed ID: 15964386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
    Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
    Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine.
    El Haggan W; Ficheux M; Debruyne D; Rognant N; Lobbedez T; Allard C; Coquerel A; Ryckelynck JP; Hurault de Ligny B
    Transplant Proc; 2005 Mar; 37(2):864-6. PubMed ID: 15848558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs.
    Araki M; Flechner SM; Ismail HR; Flechner LM; Zhou L; Derweesh IH; Goldfarb D; Modlin C; Novick AC; Faiman C
    Transplantation; 2006 Feb; 81(3):335-41. PubMed ID: 16477217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury.
    Ruggenenti P; Perico N; Gotti E; Cravedi P; D'Agati V; Gagliardini E; Abbate M; Gaspari F; Cattaneo D; Noris M; Casiraghi F; Todeschini M; Cugini D; Conti S; Remuzzi G
    Transplantation; 2007 Oct; 84(8):956-64. PubMed ID: 17989600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The utilization of sirolimus and the impact on wound-healing complications in obese kidney transplant recipients.
    Hulbert AL; Delahunty AJ; Rajab A; Forbes RC; Winters HA
    Clin Transplant; 2013; 27(4):E521-7. PubMed ID: 23923974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term follow-up of 100 high-risk renal transplant recipients converted from calcineurin inhibitors to sirolimus: a single center experience.
    Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Tawab KA; Balaha MA; Abraham M; Said T; Nair MP; Al-Waheeb S; Al-Muzairai I; Nampoory MR
    Transplant Proc; 2009 Jun; 41(5):1666-70. PubMed ID: 19545704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients.
    Knight RJ; Villa M; Laskey R; Benavides C; Schoenberg L; Welsh M; Kerman RH; Podder H; Van Buren CT; Katz SM; Kahan BD
    Clin Transplant; 2007; 21(4):460-5. PubMed ID: 17645704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conversion from mycophenolate mofetil to azathioprine in high-risk renal allograft recipients on cyclosporine-based immunosuppression.
    Lou HX; Vathsala A
    Transplant Proc; 2004 Sep; 36(7):2090-1. PubMed ID: 15518756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Steroid withdrawal five days after renal transplantation allows for the prevention of wound-healing complications associated with sirolimus therapy.
    Sandrini S; Setti G; Bossini N; Maffei C; Iovinella L; Tognazzi N; Maffeis R; Nodari F; Portolani N; Cancarini G
    Clin Transplant; 2009; 23(1):16-22. PubMed ID: 18727661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sirolimus attenuates the rate of progression of early chronic allograft nephropathy.
    Sumethkul V; Changsirikulchai S; Lothuvachai T; Chalermsanyakorn P
    Transplant Proc; 2006 Dec; 38(10):3470-2. PubMed ID: 17175307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of 2-gram versus 1-gram concentration controlled mycophenolate mofetil on renal transplant outcomes using sirolimus-based calcineurin inhibitor drug-free immunosuppression.
    Flechner SM; Feng J; Mastroianni B; Savas K; Arnovitz J; Moneim H; Modlin CS; Goldfarb D; Cook DJ; Novick AC
    Transplantation; 2005 Apr; 79(8):926-34. PubMed ID: 15849545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Corticosteroid avoidance ameliorates lymphocele formation and wound healing complications associated with sirolimus therapy.
    Rogers CC; Hanaway M; Alloway RR; Alexander JW; Boardman RE; Trofe J; Gupta M; Merchen T; Buell JF; Cardi M; Roy-Chaudhury P; Succop P; Woodle ES
    Transplant Proc; 2005 Mar; 37(2):795-7. PubMed ID: 15848534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conversion from cyclosporine to sirolimus in stable renal transplant recipients.
    Sennesael JJ; Bosmans JL; Bogers JP; Verbeelen D; Verpooten GA
    Transplantation; 2005 Dec; 80(11):1578-85. PubMed ID: 16371929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are wound complications after a kidney transplant more common with modern immunosuppression?
    Humar A; Ramcharan T; Denny R; Gillingham KJ; Payne WD; Matas AJ
    Transplantation; 2001 Dec; 72(12):1920-3. PubMed ID: 11773889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report.
    Kobashigawa JA; Miller LW; Russell SD; Ewald GA; Zucker MJ; Goldberg LR; Eisen HJ; Salm K; Tolzman D; Gao J; Fitzsimmons W; First R;
    Am J Transplant; 2006 Jun; 6(6):1377-86. PubMed ID: 16686761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study.
    Abramowicz D; Del Carmen Rial M; Vitko S; del Castillo D; Manas D; Lao M; Gafner N; Wijngaard P;
    J Am Soc Nephrol; 2005 Jul; 16(7):2234-40. PubMed ID: 15917338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New immunosuppressive treatment in kidney transplantation.
    Di Landro D; Sarzo G; Marchini F
    Clin Nephrol; 2000 Apr; 53(4):suppl 23-32. PubMed ID: 10809431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.